Topobexin

Topobexin (Topobexin 9) is a highly selective inhibitor for TOP2B. Topobexin selectively inhibits TOP2B in vitro and immobilizes TOP2B on DNA. Topobexin demonstrates significant protection of cardiomyocytes against DAU-induced damage. Topobexin prevents anthracycline-induced cardiotoxicity and DAU-induced decrease in LV systolic function in vivo with rabbit model[1].

Product Specifications

CAS Number

[3076446-44-8]

UNSPSC

12352005

Target

Topoisomerase

Related Pathways

Cell Cycle/DNA Damage

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Purity

99.04

Smiles

CCCC1=CC(OC2=C(C(OCCN3CCN(CC3)C)=CC=C12)C(N4CCCC5=C4C=CC=C5)=O)=O

Molecular Formula

C29H35N3O4

Molecular Weight

489.61

References & Citations

[1]Kubeš, J., et al., (2025) . Topobexin targets the Topoisomerase II ATPase domain for beta isoform-selective inhibition and anthracycline cardioprotection. Nature communications, 16 (1), 4928.